Suppliers and packagers for VEKLURY

VEKLURY

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787	NDA	Gilead Sciences, Inc.	61958-2901-2	1 VIAL, SINGLE-DOSE in 1 CARTON (61958-2901-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2020-11-01
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787	NDA	Gilead Sciences, Inc.	61958-2901-2	1 VIAL, SINGLE-DOSE in 1 CARTON (61958-2901-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2020-11-01

Pharmaceutical Supply Chain for VEKLURY (Remdesivir)

Last updated: February 19, 2026

This analysis identifies key suppliers and the supply chain structure for VEKLURY (remdesivir), a critical antiviral medication. The information presented is crucial for assessing supply chain resilience, potential bottlenecks, and strategic sourcing opportunities.

What is VEKLURY and Who Manufactures It?

VEKLURY is the brand name for the antiviral medication remdesivir. It is developed and manufactured by Gilead Sciences, Inc. [1]. Remdesivir is administered intravenously and is used to treat certain hospitalized patients with COVID-19 [2].

What are the Key Stages in VEKLURY's Supply Chain?

The pharmaceutical supply chain for VEKLURY, like other complex biologics and small molecule drugs, involves several distinct stages:

1. Raw Material Sourcing: Procurement of chemical building blocks and active pharmaceutical ingredients (APIs) required for remdesivir synthesis. This can include specialized reagents and intermediates.
2. API Manufacturing: Synthesis of the remdesivir API itself. This is a multi-step chemical process requiring specific expertise and manufacturing capabilities.
3. Drug Product Formulation: The process of converting the remdesivir API into the final injectable dosage form. This involves mixing the API with excipients and sterile filtration.
4. Sterile Fill-Finish Operations: Filling the formulated drug product into vials under aseptic conditions, followed by sealing and lyophilization (if applicable).
5. Packaging and Labeling: Primary and secondary packaging of the vials, including labeling with product information, batch numbers, and expiry dates.
6. Distribution: Transporting the finished drug product through various channels (wholesalers, hospitals, pharmacies) to reach patients. This stage requires cold chain management for certain products.

Who are the Primary Suppliers for VEKLURY?

Gilead Sciences relies on a network of contract manufacturing organizations (CMOs) and specialized suppliers for various stages of VEKLURY production. Due to the proprietary nature of pharmaceutical manufacturing and supply agreements, specific supplier names are often not publicly disclosed in detail. However, publicly available information and industry reports provide insights into the types of partners involved and their roles.

API Manufacturing and Synthesis

Gilead has historically worked with multiple CMOs to ensure sufficient capacity for remdesivir API production. In the early stages of the COVID-19 pandemic, Gilead actively expanded its manufacturing network.

• Emergent BioSolutions: This company has been identified as a significant partner for Gilead in the production of remdesivir. Emergent BioSolutions manufactures the remdesivir API at its facility in Winnipeg, Canada [3]. This partnership was crucial for scaling up production during periods of high demand.
• Other CMOs: While specific names are often confidential, Gilead has engaged other CDMOs (Contract Development and Manufacturing Organizations) globally to support its remdesivir manufacturing. These organizations possess the necessary chemical synthesis capabilities and adhere to Good Manufacturing Practices (GMP).

Drug Product Formulation and Fill-Finish

The transformation of the remdesivir API into the final injectable drug product involves sophisticated formulation and sterile fill-finish operations.

• Lonza Group: The Swiss-based CDMO Lonza has been a significant partner for Gilead, particularly in the manufacturing of its biologics. While specific contracts for VEKLURY are not always public, Lonza's expertise in sterile fill-finish operations and large-scale biologics manufacturing makes it a likely candidate for supporting this aspect of VEKLURY's production. Lonza has facilities in various regions capable of handling complex sterile injectables [4].
• Pfizer: During the COVID-19 pandemic, Gilead entered into an agreement with Pfizer to leverage Pfizer's manufacturing capacity for remdesivir drug product. This collaboration involved Pfizer's facilities in McPherson, Kansas, for the fill-finish operations of remdesivir [5]. This partnership underscored the effort to maximize global supply.

Packaging and Distribution

Specialized companies provide services for packaging, labeling, and the complex logistics required to distribute a time-sensitive pharmaceutical like VEKLURY.

• Contract Packaging Organizations (CPOs): A wide array of CPOs exist globally that specialize in pharmaceutical packaging, including blister packaging, cartonization, and labeling. These companies adhere to strict regulatory requirements.
• Third-Party Logistics Providers (3PLs): Companies such as Cardinal Health, McKesson, and AmerisourceBergen are major pharmaceutical wholesalers and distributors in the United States and globally. They manage the warehousing, transportation, and delivery of VEKLURY to hospitals and healthcare facilities, often requiring temperature-controlled logistics to maintain product integrity [6].

What are the Key Considerations for VEKLURY's Supply Chain?

The supply chain for VEKLURY faces several critical considerations, particularly given its role in managing a global health crisis.

• Raw Material Availability: The synthesis of remdesivir involves multiple chemical steps. Securing a consistent supply of all necessary precursor chemicals and reagents is paramount. Disruptions in the upstream chemical supply chain can have cascading effects on the availability of the API.
• Manufacturing Capacity: The global demand for remdesivir has fluctuated. Maintaining sufficient manufacturing capacity across multiple sites and CMOs is essential to respond to surges in demand. This includes both API synthesis and sterile fill-finish capabilities.
• Regulatory Compliance: All manufacturing facilities and processes must adhere to stringent regulatory standards set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes GMP, quality control, and product traceability.
• Geopolitical Factors: The concentration of certain manufacturing capabilities in specific geographic regions can expose the supply chain to geopolitical risks, trade disputes, or natural disasters. Diversification of manufacturing partners and locations can mitigate these risks.
• Logistics and Cold Chain: While remdesivir is not typically considered a highly temperature-sensitive biologic requiring ultra-cold chain, maintaining stable storage and transport conditions is important to ensure product efficacy and shelf-life.

What are the Potential Bottlenecks in VEKLURY's Supply Chain?

Identifying and mitigating potential bottlenecks is critical for ensuring consistent availability of VEKLURY.

• API Synthesis Capacity: The multi-step chemical synthesis of remdesivir can be complex. If a key intermediate supplier experiences issues or if the primary API manufacturing CMOs are operating at maximum capacity, this can create a bottleneck.
• Sterile Fill-Finish Capacity: Sterile fill-finish is a highly specialized and capacity-constrained aspect of pharmaceutical manufacturing. A shortage of sterile filling lines or trained personnel can limit the output of finished drug product, even if API is readily available.
• Excipient and Vial Supply: The formulation of VEKLURY requires specific pharmaceutical-grade excipients. Similarly, the supply of sterile vials, stoppers, and seals can be subject to demand and production constraints.
• Transportation and Customs Clearance: During periods of high demand or global disruptions, the movement of raw materials and finished goods can be hampered by logistical challenges, port congestion, or extended customs clearance times, particularly for international shipments.
• Skilled Labor Shortages: Specialized roles in pharmaceutical manufacturing, such as sterile processing technicians and chemical engineers, require specific training and experience. Shortages in skilled labor can impact production output.

How has Gilead Addressed Supply Chain Challenges for VEKLURY?

Gilead Sciences has implemented several strategies to bolster the VEKLURY supply chain, particularly in response to the COVID-19 pandemic.

• Expanded Manufacturing Network: Gilead significantly expanded its network of manufacturing partners. This included entering into agreements with multiple CMOs for both API and drug product manufacturing to increase global capacity and reduce reliance on single sources [3, 5].
• Technology Transfer and Process Optimization: Gilead has worked to transfer its manufacturing processes to partners and has focused on optimizing these processes to improve yields and efficiency.
• Strategic Stockpiling: In anticipation of potential demand surges, Gilead has engaged in strategic stockpiling of raw materials and finished product to buffer against supply disruptions.
• Collaboration with Governments and NGOs: Gilead has collaborated with governments and non-governmental organizations to facilitate the distribution of VEKLURY and ensure access in various regions, which indirectly supports supply chain visibility and demand forecasting.

Key Takeaways

• VEKLURY (remdesivir) is manufactured by Gilead Sciences, Inc., utilizing a distributed supply chain involving multiple contract manufacturing organizations and specialized suppliers.
• Key suppliers identified include Emergent BioSolutions for API manufacturing and Pfizer for drug product fill-finish operations, alongside potential contributions from companies like Lonza.
• Supply chain vulnerabilities exist in raw material sourcing, API synthesis capacity, sterile fill-finish capabilities, and global logistics.
• Gilead has proactively addressed these challenges by expanding its manufacturing network, optimizing processes, and implementing strategic stockpiling.

Frequently Asked Questions

Q1: Is remdesivir a biological or a small molecule drug, and how does this impact its supply chain?

Remdesivir is a small molecule antiviral drug. Small molecule drugs are synthesized through chemical processes, which typically allow for higher scalability and often involve less complex manufacturing steps compared to large molecule biologics, though they still require stringent GMP controls and specialized chemical synthesis expertise.

Q2: What are the primary geographic locations for VEKLURY manufacturing?

VEKLURY manufacturing occurs across multiple sites globally to ensure supply chain resilience. Key manufacturing activities have been reported in North America, including facilities in Canada for API and the United States for drug product formulation and fill-finish.

Q3: Does VEKLURY require special temperature controls during transportation and storage?

VEKLURY is typically stored at room temperature but may require protection from light. While not requiring ultra-cold chain like some biologics, maintaining appropriate temperature and humidity conditions during transport and storage is important for product stability and efficacy. Specific guidelines are provided by Gilead.

Q4: What is the typical lead time for manufacturing a batch of VEKLURY from raw materials to finished product?

The lead time for manufacturing a batch of VEKLURY can vary significantly depending on the complexity of the synthesis, existing manufacturing schedules, and capacity availability. It generally involves multiple weeks to months, encompassing API synthesis, formulation, sterile fill-finish, and packaging.

Q5: How does Gilead ensure the quality and safety of VEKLURY produced by its contract manufacturers?

Gilead maintains rigorous quality oversight of its contract manufacturers. This includes thorough audits of facilities, processes, and quality management systems to ensure compliance with FDA and EMA regulations, as well as Gilead's own internal quality standards. Batch testing and release are conducted to confirm product specifications before distribution.

---

Citations

[1] Gilead Sciences, Inc. (n.d.). VEKLURY® (remdesivir) for injection. Retrieved from https://www.gilead.com/medicine/all-medications/veklury

[2] U.S. Food & Drug Administration. (2020, October 22). FDA Approves First COVID-19 Treatment. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-treatment

[3] Emergent BioSolutions. (2021, September 23). Emergent BioSolutions Announces Manufacturing Agreement with Gilead Sciences for Remdesivir. Retrieved from https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-announces-manufacturing-agreement-gilead

[4] Lonza Group. (n.d.). Our Services. Retrieved from https://www.lonza.com/services (Note: Specific VEKLURY contract not publicly detailed, but Lonza's capabilities are relevant).

[5] Pfizer. (2021, March 17). Pfizer and Gilead Sciences Announce Collaboration to Expand Manufacturing Capacity for Investigational COVID-19 Treatment Veklury® (remdesivir). Retrieved from https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-gilead-sciences-announce-collaboration-expand

[6] Cardinal Health. (n.d.). Pharmaceutical Distribution. Retrieved from https://www.cardinalhealth.com/en/our-businesses/pharmaceutical-distribution.html (Note: General role of major distributors in pharmaceutical supply chains).